DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
ASN002 is an investigational drug.
There have been 7 clinical trials for ASN002. The most recent clinical trial was a Phase 1 trial, which was initiated on September 29th 2018.
The most common disease conditions in clinical trials are Dermatitis, Eczema, and Dermatitis, Atopic. The leading clinical trial sponsors are Asana BioSciences and [disabled in preview].
There are four US patents protecting this investigational drug and thirty international patents.
Recent Clinical Trials for ASN002
|Phase 2 Study to Evaluate ASN002 in Subjects With Severe Chronic Hand Eczema||Asana BioSciences||Phase 2|
|Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male Subjects||Asana BioSciences||Phase 1|
|Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis||Asana BioSciences||Phase 2|
Top disease conditions for ASN002
Top clinical trial sponsors for ASN002
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|ASN002||Start Trial||Pyrimido-pyridazinone compounds and methods of use thereof||Asana BioSciences, LLC (Lawrenceville, NJ)||Start Trial|
|ASN002||Start Trial||Uses of pyrimido-pyridazinones to treat cancer||Asana BioSciences, LLC (Lawrenceville, NJ)||Start Trial|
|ASN002||Start Trial||Pyrimido-pyridazinone compounds and methods of use thereof||Endo Pharmaceuticals Inc. (Malvern, PA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|